Introduction
Our policies and position statements have been developed in partnership with our clinical experts for use by health professionals and clinical teams in NHS North West London ICB. They aim to ensure patients consistently access medicines with safe, clinical, and cost-effective outcomes.
Policies |
|
|
High Cost Drugs routinely commissioned in North West London 2024 / 25 |
Medicines not reimbursed through national prices funded by NHS North West London ICB |
|
This policy, developed in collaboration with system partners involved in NHS prescribing and drug services, outlines best practice recommendations for medicines prescribed in North West London. |
|
Position Statements |
|
|
Continuous Glucose Monitoring (CGM) in people with Type 1 Diabetes Mellitus |
This document outlines the North West London recommendations for continuous glucose monitoring (CGM) for all adults with Type 1 Diabetes, in line with NICE guidance (NG17). |
|
NHSE has released an FAQ on the rollout of tirzepatide (Mounjaro®) in the NHS. The final guidance is set for release on 23 December 2024. |
|
|
Updated position statement: Wegovy® for managing overweight and obesity |
This document provides an update on the prescribing agreement for Wegovy® as a treatment for managing overweight and obesity in North West London. |
Primary Care Rebate Scheme |
|
|
This document lists the primary care rebate schemes NHS North West London is currently signed up to. |
|